Table 2.

Intratumoral heterogeneity in nine patients with primary resected Barrett carcinoma in biopsy and tumor tissue

PatientBiopsyMedian tumorRange tumor (min-max)
A. Expression levels of MTHFR, ERCC4, caldesmon, and MRP1 (gene/GAPDH)
MTHFR
    a1.781.611.59-3.13
    b1.380.480.14-1.38
    c4.091.971.40-3.14
    d1.610.430.12-0.87
    e6.142.702.29-6.45
    f3.801.130.77-1.81
    g0.441.620.56-2.00
    h1.150.480.38-1.40
    i0.460.960.58-1.34
ERCC4
    a1.471.330.83-3.17
    b0.550.390.26-0.69
    c2.140.570.32-1.91
    d1.000.810.41-1.01
    e2.552.31.07-2.61
    f1.130.590.30-1.06
    g2.142.071.29-2.71
    h2.011.470.75-1.97
    i1.650.650.49-0.95
Caldesmon
    a0.651.651.23-2.44
    b0.830.890.59-1.75
    c2.850.960.80-1.98
    d0.540.350.25-0.45
    e6.6415.196.12-16.08
    f2.201.040.77-1.47
    g0.991.710.81-2.47
    h0.720.710.52-1.49
    i1.001.280.77-1.47
MRP1
    a2.431.130.67-1.94
    b1.270.590.29-1.52
    c1.90.980.63-1.27
    d1.690.570.44-1.17
    e3.751.040.33-1.84
    f2.570.730.34-0.91
    g2.071.970.94-3.12
    h1.950.640.50-0.87
    i1.210.410.34-0.56
B. Expression levels of HER-2/neu (gene/GAPDH)
HER-2/neu
    a246.2110.8786.55-132.61
    b1.691.561.02-4.00
    c3.492.391.65-2.73
    d5.044.131.83-4.63
    e6.573.912.70-4.57
    f21.317.568.54-23.88
    g2.654.373.20-5.30
    h2.881.390.96-1.87
    i1.420.990.31-1.49
  • NOTE: Tumor gene expression was determined by analysis of five different areas (median; range, minimum-maximum).